Sodium-glucose co-transporter 2 inhibition prior to atrial fibrillation ablation: A pilot randomised controlled trial

Phase 1

• Conditions: Atrial fibrillation; Cardiovascular - Other cardiovascular diseases

• Registration Number: ACTRN12621000685819
• Lead Sponsor: Flinders University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-06-04
• Last Update Posted: 14 June 2021

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients referred for clinically indicated AF ablation

Exclusion Criteria

People under the age of 18.
Patients who are unable or unwilling to provide consent.
Considerations related to AF ablation procedure (presence of left atrial thrombus, previous AF ablation, contraindication to anticoagulation).
Exclusions related to SGLT2 commencement; patients already taking SGLT2 inhibitors, history of impaired kidney function (eGFR <45mL/min/1.73m2), Child-Pugh Class C liver disease, pregnancy/ breastfeeding, symptomatic hypotension/ systolic blood pressure <100mmHg, type 1 diabetes mellitus, or previous SGLT2 intolerance or allergy, in line with current published contraindications to therapy.

Study & Design

• Study Type: Interventional
• Study Design: Not specified